Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin, Losartan, and Simvastatin in Hospitalized COVID-19
NCT04343001Phase 3Withdrawn
- Sponsor
- London School of Hygiene & Tropical Medicine
- Start
- Oct 2020
- Primary completion
- Apr 2021
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of aspirin, losartan and simvastatin in coronavirus disease 2019 (COVID-19) (8 arms), sponsored by London School of Hygiene & Tropical Medicine. Primary endpoint: Death at 28 days. Planned start Oct 2020; status: withdrawn.
02
Drugs
aspirinlosartansimvastatin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04343001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04343001.